For US Healthcare Professionals Only
40 result(s)
298 result(s)
Rethinking Seizure Emergencies: Expert Perspectives on a New Paradigm
19th International Child Neurology Congress (ICNC), 2026
A checklist to support the diagnosis of Lennox-Gastaut syndrome
International Epilepsy Congress (IEC), 2025
A checklist to support the diagnosis of Lennox-Gastaut syndrome
International Epilepsy Congress (IEC), 2025
A European Study of the Effectiveness of Risk Minimisation Measures for Fenfluramine Oral Solution in Dravet Syndrome and Lennox-Gastaut Syndrome
Symposium on Hidradenitis Suppurativa Advances (SHSA), 2025
A Longitudinal Study of Quality of Life and Depression in Patients with Hidradenitis Suppurativa
International Epilepsy Congress (IEC), 2025
A Retrospective Claims Study Evaluating Mortality in Patients With Lennox-Gastaut or Dravet Syndromes in the United States
International Epilepsy Congress (IEC), 2025
A Stratified Analysis of Efficacy and Safety of Fenfluramine in Patients With Dravet Syndrome
American Epilepsy Society (AES), 2025
AAV Gene Therapy in Juvenile Mice of STXBP1 Haploinsufficiency
American Epilepsy Society (AES), 2025
AAV Mediated Overexpression of STXBP1 Variants in a Mouse Model of STXBP1 Haploinsufficiency
American College of Rheumatology (ACR), 2025
Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
European Alliance of Associations for Rheumatology (EULAR), 2025
Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS Inactive Disease in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Trials
European Academy of Dermatology and Venereology (EADV), 2025
Achieving complete skin clearance was associated with cumulative benefits on disease impact up to 2 years in patients with psoriatic arthritis and psoriasis treated with bimekizumab
American College of Rheumatology (ACR), 2025
Alternative Definitions of Moderate Flares that Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial
American College of Rheumatology (ACR), 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
American College of Rheumatology (ACR), 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-World Clinical Practice
European Epilepsy Congress (EEC), 2024
Analysis of Safety, Tolerability and Clinical Global Impression-Improvement Scale Ratings in Patients With Dravet Syndrome Enrolled as Adults in a Fenfluramine Open-Label Extension Study
European Pediatric Neurology Society (EPNS), 2025
Antiseizure Medication Regimen Adjustment After Fenfluramine Initiation: Lessons Learned From European Early Access Program in Pediatric and Adult Patients With Dravet Syndrome
American College of Rheumatology (ACR), 2025
Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modif
19th International Child Neurology Congress (ICNC), 2026
Association of Fenfluramine Treatment and Everyday Executive Function in Preschool-Aged Children With Lennox-Gastaut Syndrome
American Academy of Neurology (AAN), 2026
Association of Fenfluramine Treatment and Everyday Executive Functioning in Adults With Lennox-Gastaut Syndrome
18th Eilat Conference on New Antiepileptic Drugs and Devices, 2026
Association of Fenfluramine Treatment and Everyday Executive Functioning in Adults With Lennox-Gastaut Syndrome
American Epilepsy Society (AES), 2025
Association of Fenfluramine Treatment and Everyday Executive Functioning in Adults With Lennox-Gastaut Syndrome
European Epilepsy Congress (EEC), 2024
Automated assessment of sleep in healthy pediatrics from simulated behind-the-ear EEG
International Epilepsy Congress (IEC), 2025
Barriers to and benefits of identifying patients with developmental and epileptic encephalopathies in adult care settings
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Bimekizumab 2-year impact on HSSQ skin pain in moderate to severe HS: data from BE HEARD EXT
Symposium on Hidradenitis Suppurativa Advances (SHSA), 2025
Bimekizumab 3-Year Efficacy and Safety in Patients with HS: Results from BE HEARD I&II and EXT
International Congress of Dermatology (ICD), 2025
Bimekizumab 3-year efficacy in patients with psoriasis and risk factors for progression to psoriatic arthritis or screening positive for psoriatic arthritis: Long-term results from BE BRIGHT and BE RADIANT
American College of Rheumatology (ACR), 2025
Bimekizumab 3-Year Efficacy in Patients With Psoriasis and Risk Factors for Progression to Psoriatic Arthritis or Screening Positive for Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
International Congress of Dermatology (ICD), 2025
Bimekizumab 5-year maintenance of response in US and Canadian patients with psoriasis who responded at Week 16
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Bimekizumab achievement of ‘super response’ using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Fall Clinical (FC), 2025
Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II
Congress of Clinical Dermatology (CCD), 2025
Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II
International Congress of Dermatology (ICD), 2025
Bimekizumab cumulative health-related quality of life benefit by clinical response in patients with hidradenitis suppurativa: 1 year data from BE HEARD I&II
American College of Rheumatology (ACR), 2025
Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
American College of Rheumatology (ACR), 2025
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab demonstrated long-term efficacy and safety in patients with active psoriatic arthritis who had baseline plaque-type psoriasis and nail involvement: Up to 3-year results from two phase 3 studies
European Alliance of Associations for Rheumatology (EULAR), 2025
Bimekizumab Demonstrated Similar Efficacy and Safety in Two Clinical Endotypes of Axial Spondyloarthritis: 1-Year Results from Two Phase 3 Trials
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab demonstrated sustained efficacy and safety across the full spectrum of axial spondyloarthritis: 3-year results from two phase 3 studies and their open-label extension
European Alliance of Associations for Rheumatology (EULAR), 2025
Bimekizumab Demonstrated Sustained Efficacy and Safety Across the Full Spectrum of Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies and Their Open-Label Extension
European Alliance of Associations for Rheumatology (EULAR), 2025
Bimekizumab Demonstrates Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
American Academy of Dermatology (AAD), 2026
Bimekizumab Demonstrates Sustained Improvements in Pain, Morning Stiffness, and Fatigue in Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies
Winter Clinical Miami, 2026
Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Studies
American Academy of Dermatology (AAD), 2026
Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab effect on health-related quality of life and symptoms over 2 years: Data from BE HEARD EXT
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab efficacy and safety in Chinese patients with moderate to severe plaque psoriasis in the BE SHINING phase 3, multicentre, randomised, double-blinded, placebo-controlled study
RheumNow Live (RNL), 2025
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
RheumNow Live (RNL), 2025
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab efficacy and safety through 3 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and their open-label extension BE HEARD EXT
Maui Derm Hawaii, 2026
Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT
Winter Clinical Hawaii, 2026
Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT
Winter Clinical Miami, 2026
Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT
Congress of Clinical Dermatology (CCD), 2025
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Maui Derm NP+PA Summer, 2025
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Society of Dermatology Physician Assistants (SDPA) Summer, 2025
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
DERM NP/PA Conference (DERM), 2025
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
American College of Rheumatology (ACR), 2025
Bimekizumab Efficacy and Safety Through 5 Years in Patients with Moderate to Severe Plaque Psoriasis in the US and Canada
American Academy of Dermatology (AAD), 2026
Bimekizumab Efficacy by Disease Duration and Severity in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results From BE HEARD EXT
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Bimekizumab efficacy by patient subgroups in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
American Academy of Dermatology (AAD), 2026
Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results From BE HEARD EXT
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: Percentage change from baseline through 4 years from BE BRIGHT
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab efficacy on IHS4 response levels and draining tunnels by HS disease duration over 2 years: Data from BE HEARD EXT
American Academy of Dermatology (AAD), 2026
Bimekizumab Efficacy on IHS4 Response Levels and Lesions by HS Disease Duration Over 2 Years: Data from BE HEARD EXT
International Congress of Dermatology (ICD), 2025
Bimekizumab impact on draining tunnel and lesion count over 2 years in hidradenitis suppurativa: Data from BE HEARD EXT
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Bimekizumab impact on draining tunnels over 2 years in HS: data from BE HEARD EXT
International Congress of Dermatology (ICD), 2025
Bimekizumab impact on efficacy and patient-reported outcomes in moderate versus severe hidradenitis suppurativa
DERM NP/PA Conference (DERM), 2025
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Fall Clinical (FC), 2025
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Society of Dermatology Physician Assistants (SDPA) Summer, 2025
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Maui Derm NP+PA Summer, 2025
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab impact on hidradenitis suppurativa lesions over 2 years: Data from BE HEARD EXT
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Bimekizumab impact on pain and quality of life stratified by IHS4 levels in patients with hidradenitis suppurativa: 2-year results from BE HEARD EXT
Maui Derm Hawaii, 2026
Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT
Winter Clinical Hawaii, 2026
Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT
Symposium on Hidradenitis Suppurativa Advances (SHSA), 2025
Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT
Winter Clinical Miami, 2026
Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT
Congress of Clinical Rheumatology (CCR) East, 2026
Bimekizumab Improves Skin Pain Over 3 Years in Hidradenitis Suppurativa: Data from BE HEARD EXT
Congress of Clinical Rheumatology (CCR) East, 2026
Bimekizumab in Patients with Psoriatic Arthritis Resulted in Sustained Efficacy Assessed Using Composite Outcome Measures to 3 Years
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab influences the association between HS skin pain severity and health-related quality of life over 2 years: Data from BE HEARD EXT
American Academy of Dermatology (AAD), 2026
Bimekizumab Leads to Sustained Flare-Free Status in Moderate to Severe Hidradenitis Suppurativa: 3-Year Data from BE HEARD EXT
Symposium on Hidradenitis Suppurativa Advances (SHSA), 2025
Bimekizumab Lesion Resolution Over 3 Years in HS: Results from BE HEARD I&II and BE HEARD EXT
Congress of Clinical Rheumatology (CCR) East, 2026
Bimekizumab Long-Term Efficacy and Safety in Patients with Psoriatic Arthritis with Baseline Plaque Psoriasis/Nail Involvement to 3 Years
DERM NP/PA Conference (DERM), 2025
Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Improvements in mean absolute clinical outcome scores over 4 years
Fall Clinical (FC), 2025
Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Improvements in mean absolute clinical outcome scores over 4 years
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab long-term incidence of psoriatic arthritis symptoms and psoriatic arthritis adverse events in patients with psoriasis and risk factors for disease progression
Winter Clinical Miami, 2026
Bimekizumab Long-Term On-Treatment Remission and Associated Sustained Improvements in Quality of Life in Moderate to Severe Plaque Psoriasis Across Five Phase 3/3b Trials
European Alliance of Associations for Rheumatology (EULAR), 2025
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
International Congress of Dermatology (ICD), 2025
Bimekizumab maintenance of efficacy over 4 years in biologic-naïve andbiologic-experienced patients with moderate to severe plaque psoriasis
Society of Dermatology Physician Assistants (SDPA) Summer, 2025
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
Maui Derm NP+PA Summer, 2025
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
International Congress of Dermatology (ICD), 2025
Bimekizumab maintenance of response during treatment interruption and retreatment in US/Canadian patients with psoriasis
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab maintenance of response over 2 years: Data from BE HEARD EXT
Symposium on Hidradenitis Suppurativa Advances (SHSA), 2025
Bimekizumab Mental Health Outcomes in Patients with HS: 2-Year Data from BE HEARD EXT
American Academy of Dermatology (AAD), 2026
Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis
American Academy of Dermatology (AAD), 2026
Bimekizumab pharmacokinetics, safety, and efficacy in adolescents with moderate to severe plaque psoriasis: Data from the initial treatment period of the open-label BE CONNECTED phase 2 study
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies
Fall Clinical (FC), 2025
Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies
Symposium on Hidradenitis Suppurativa Advances (SHSA), 2025
Bimekizumab Reduces Draining Tunnel Count Over 3 Years in HS: Data from BE HEARD EXT
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab reduces systemic inflammation and cardiovascular risk gene signatures in psoriatic disease
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab remission and high disease control over 4 years in patients with psoriasis achieving complete skin clearance at Week 16: Results from four phase 3 trials
Winter Clinical Miami, 2026
Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials
Winter Clinical Hawaii, 2026
Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials
Maui Derm Hawaii, 2026
Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab response in the nail matrix and nail bed through 3 years in patients with moderate to severe plaque psoriasis
Congress of Clinical Rheumatology (CCR) East, 2026
Bimekizumab Resulted in Sustained Improvements in Routine Assessment of Patient Index Data 3 (RAPID3) in Psoriatic Arthritis up to 3 Years
American Academy of Dermatology (AAD), 2026
Bimekizumab safety and sustained long-term efficacy in patients with active psoriatic arthritis and baseline psoriasis: Up to 3-year results from two phase 3 studies
International Congress of Dermatology (ICD), 2025
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
Maui Derm Hawaii, 2026
Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials
Winter Clinical Miami, 2026
Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials
Winter Clinical Hawaii, 2026
Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials
European Academy of Dermatology and Venereology (EADV), 2025
Bimekizumab safety in patients with psoriasis achieving complete skin clearance: 4-year analysis from 5 phase 3/3b trials
American Academy of Dermatology (AAD), 2026
Bimekizumab time to clinical response and achievement of clinically meaningful improvement thresholds in Chinese patients with psoriasis from the BE SHINING phase 3 trial
International Congress of Dermatology (ICD), 2025
Bimekizumab time to onset of PASI response in patients with psoriasis in three head-to-head phase 3/3b studies
Congress of Clinical Rheumatology West (CCR West), 2025
Bimekizumab Treatment in Psoriatic Arthritis Resulted in Sustained Efficacy Assessed Using Composite Outcome Measures to 3 Years
North Carolina Rheumatology Association (NCRA), 2025
Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two phase 3 studies
American Academy of Dermatology (AAD), 2026
Bimekizumab treatment resulted in long-term maintenance of complete clinical resolution across skin, joint, and nail domains in patients with active psoriatic arthritis: 3-year results from two phase 3 studies
American College of Rheumatology (ACR), 2025
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3 Year Results from Two Phase 3 Studies
American College of Rheumatology (ACR), 2025
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
American College of Rheumatology (ACR), 2025
Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
State of Texas Association of Rheumatologist (STAR), 2025
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
RheumNow Live (RNL), 2025
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
European Alliance of Associations for Rheumatology (EULAR), 2025
Bimekizumab, a Dual Inhibitor of IL-17A and IL-17F, Demonstrated Long-Term Safety and Efficacy in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: Final 3-Year Results from the Phase 3 BE OPTIMAL Study and its Open-Label Extension
American Epilepsy Society (AES), 2025
Bridging the Divide: Enhancing Communication Between People Living With an Epilepsy and Their Healthcare Providers to Improve Care
European Epilepsy Congress (EEC), 2024
Brivaracetam adjunctive therapy in earlier treatment lines in adults with focal-onset seizures in Europe and Canada: second interim results of 12-month real-world data from BRITOBA
International Epilepsy Congress (IEC), 2025
Brivaracetam Adjunctive Therapy in Paediatric and Adult Patients With Focal-Onset Seizures in Mid-European Countries: 12-Month, Real-World Outcomes from the BRIVA-REG Study
European Pediatric Neurology Society (EPNS), 2025
Brivaracetam Adjunctive Therapy in Paediatric and Adult Patients With Focal-Onset Seizures in Mid-European Countries: 12-Month, Real-World Outcomes From the BRIVA-REG Study
United Mitochondrial Medicine Foundation (UMDF) Mitochondrial Medicine Conference, 2025
Burden and impact of caring for those with thymidine kinase 2 deficiency (TK2d): results from the Assessment of TK2d Patient Perspectives (ATP) study
International Epilepsy Congress (IEC), 2025
Characterising Patient and Caregiver Experiences Resulting From Prolonged Seizures
American College of Rheumatology (ACR), 2025
Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Characteristics of patients with generalized myasthenia gravis initiating rozanolixizumab treatment in the United States
American College of Rheumatology (ACR), 2025
Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
European Epilepsy Congress (EEC), 2024
Comparative Effectiveness of Fenfluramine Versus Cannabidiol in Dravet Syndrome: A Numbers Needed to Treat Indirect Comparison Analysis
American Academy of Neurology (AAN), 2026
Comprehensive care goals in myasthenia gravis: Expert consensus recommendations using the RAND/UCLA appropriateness method
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
International Congress on Neuromuscular Diseases (ICNMD), 2024
Corticosteroid dose tapering with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT
American College of Rheumatology (ACR), 2025
Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
American Academy of Neurology (AAN), 2026
Costs, Healthcare Resource Utilization, and Patient Characteristics Associated With CDKL5 Deficiency Disorder: A Retrospective Analysis of the US Closed Claims Database MarketScan
American College of Rheumatology (ACR), 2025
Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Congress of Clinical Rheumatology West (CCR West), 2025
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
International Epilepsy Congress (IEC), 2025
Describing the Population of Patients With Prolonged Seizures: Results From a Global Real-World Point-in-Time Study
American Epilepsy Society (AES), 2025
Describing the Population of Patients With Prolonged Seizures: US Subgroup Results From a Global Real-World Point-in-Time Study
American Academy of Neurology (AAN), 2026
Describing the Population of Patients With Prolonged Seizures: US Subgroup Results From a Global Real-World Point-in-Time Study
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Developing needs-driven medical education for healthcare professionals in myasthenia gravis
European Epilepsy Congress (EEC), 2024
Development of an Electronic Decision-Assisting Tool for the Evaluation of the Likelihood of Lennox-Gastaut Syndrome (LGS) Diagnosis
American College of Medical Genetics and Genomics (ACMG), 2026
Development of functional screening for improved understanding of TK2 genetic variants
American Epilepsy Society (AES), 2025
Digital Application Usage in Epilepsy: Insight From Real-World Setting Studies BRIVA-Reg and BRITOBA
Muscular Dystrophy Association (MDA), 2026
Disease course and healthcare burden of thymidine kinase 2 deficiency (TK2d) in Rady Children’s Hospital patients
American Academy of Neurology (AAN), 2026
Disruptive Sleep in Developmental and Epileptic Encephalopathies: Interim Results of a Caregiver Survey
European Alliance of Associations for Rheumatology (EULAR), 2025
Dual Inhibition of IL-17A and IL-17F with Bimekizumab Demonstrated Long-Term Safety and Efficacy in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors
Earlier Identification and Treatment of Patients with a Developmental and Epileptic Encephalopathy (DEE): Taking A Close Look at Lennox-Gastaut Syndrome (LGS)
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Educational needs assessment of nurses involved in the care of patients with myasthenia gravis
Annual Carrell Krusen Neuromuscular Symposium (ACKNS), 2025
Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: Post hoc item-level analysis of MycarinG
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Effect of rozanolixizumab on myasthenia gravis-specific outcome subdomain scores: Post hoc analyses from the Phase 3 MycarinG study
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Effect of zilucoplan on fatigue in patients with generalized myasthenia gravis: RAISE-XT 120-week follow-up
European Epilepsy Congress (EEC), 2024
Effectiveness and Tolerability of Brivaracetam in Adults With Epilepsy Etiology of Cerebral Neoplasm, Cerebrovascular Accident, or Cranial Trauma: Pooled Data Analyses From Two Real-World Studies
International Congress of Dermatology (ICD), 2025
Efficacy and safety of bimekizumab to 2 years in patients with psoriatic arthritis by baseline psoriasis severity
Muscular Dystrophy Association (MDA), 2026
Efficacy and safety of rozanolixizumab treatment cycles in patients with generalized myasthenia gravis: Final pooled analysis of Phase 3 studies
American Epilepsy Society (AES), 2025
Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Seizures: Results of a Phase II/III, Open-Label, Randomized, Active Comparator Trial
European Epilepsy Congress (EEC), 2024
Evaluating mental health in caregivers of patients with Dravet syndrome: a systematic review
European Epilepsy Congress (EEC), 2024
Expert Consensus Recommendations on Seizure Emergencies Suitable for Rapid and Early Seizure Termination (REST) and Timing of Intervention
International Epilepsy Congress (IEC), 2025
Exposure-Response Relationships of Fenfluramine in Patients With Dravet Syndrome and Lennox-Gastaut Syndrome
International Epilepsy Congress (IEC), 2025
Expression and quantification of STXBP1 splice variants in rodent and non-human primate brain tissues
European Pediatric Neurology Society (EPNS), 2025
Fenfluramine Efficacy Trajectories in Placebo or Treatment Groups From Randomized Controlled Trial to Open-Label Extension in Patients With Lennox-Gastaut Syndrome
19th International Child Neurology Congress (ICNC), 2026
Fenfluramine in CDKL5 Deficiency Disorder: Phase III Primary Efficacy and Safety Results by Age
American Academy of Neurology (AAN), 2026
Fenfluramine in CDKL5 Deficiency Disorder: Primary Efficacy and Safety Results From a Phase 3, Randomized, Double-blind, Placebo-controlled study
American Epilepsy Society (AES), 2025
Fenfluramine in CDKL5 Deficiency Disorder: Primary Efficacy and Safety Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
European Epilepsy Congress (EEC), 2024
Fenfluramine Increases Seizure-Free Days in Patients With Lennox-Gastaut Syndrome
American Epilepsy Society (AES), 2025
Fenfluramine Persistence in Patients With Lennox-Gastaut Syndrome: A Retrospective Analysis Using US Claims Data
American Epilepsy Society (AES), 2025
Final Results From a Long-Term Open-Label Extension Study (Up to 4 Years): Tolerability of Fenfluramine and Global Functioning of Pediatric and Adult Patients With Dravet or Lennox-Gastaut Syndromes
European Pediatric Neurology Society (EPNS), 2025
Functional outcomes in patients with thymidine kinase 2 deficiency aged ≤12 years at symptom onset who received pyrimidine nucleos(t)ide therapy
European Pediatric Neurology Society (EPNS), 2025
Functional outcomes in untreated patients with thymidine kinase 2 deficiency (TK2d) aged ≤12 years at TK2d symptom onset: findings from the largest international TK2d dataset
Muscular Dystrophy Association (MDA), 2026
Genetic Prevalence of Thymidine Kinase 2-Related Mitochondrial Disease: A Combined Approach Using Clinical Literature and Large-Scale Genomic Databases
International Epilepsy Congress (IEC), 2025
Global Seizure Rescue Medication Landscape: Availability & Reimbursement
European Academy of Dermatology and Venereology (EADV), 2025
Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study
American Epilepsy Society (AES), 2025
Healthcare Resource Utilization and Antiseizure Medication Claims in Patients With Lennox-Gastaut Syndrome Receiving Fenfluramine in the United States
American Epilepsy Society (AES), 2025
Healthcare Resource Utilization and Costs With the Introduction of Intranasal Midazolam in Acute Seizure Management: A Wisconsin-Based Claims Analysis
American Academy of Neurology (AAN), 2026
Healthcare Resource Utilization, Antiseizure Medication Claims, and Treatment Persistence in Patients With Lennox-Gastaut Syndrome Receiving Fenfluramine in the United States
European Epilepsy Congress (EEC), 2024
Healthcare Utilization and Persistence in Patients With Dravet Syndrome: A Retrospective Analysis Using US Claims Data
American College of Rheumatology (ACR), 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
International Epilepsy Congress (IEC), 2025
Impact of Fenfluramine on Convulsive Seizure Frequency in Dose-capped Patients With Dravet Syndrome
American Epilepsy Society (AES), 2025
Impacts of Disruptive Seizures, Sleep, and Behaviors on Activities of Daily Living and Communication in Developmental and Epileptic Encephalopathies: Interim Results of a Caregiver Survey
19th International Child Neurology Congress (ICNC), 2026
Impacts of Disruptive Seizures, Sleep, and Behaviors on Activities of Daily Living and Communication in Developmental and Epileptic Encephalopathies: Interim Results of a Caregiver Survey
American College of Rheumatology (ACR), 2025
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Muscular Dystrophy Association (MDA), 2026
Improvement of ocular subdomain scores with zilucoplan in patients with generalized myasthenia gravis in RAISE and RAISE-XT studies
International Epilepsy Congress (IEC), 2025
Improving Lives in Dravet Syndrome: Overcoming Challenges in the Family Journey
19th International Child Neurology Congress (ICNC), 2026
Improving the developmental and epileptic encephalopathy diagnostic process: Recommendations to address the challenges
International Epilepsy Congress (IEC), 2025
In vitro electrophysiological study of hippocampal network activity in a mouse model of STXBP1 haploinsufficiency
European Alliance of Associations for Rheumatology (EULAR), 2025
Inhibition of Radiographic Progression with Bimekizumab Treatment Observed in bDMARD-Naïve Patients with Active Psoriatic Arthritis at 2 Years: Results from a Phase 3 Study and Its Open-Label Extension
European Epilepsy Congress (EEC), 2024
Insights into Lennox-Gastaut Syndrome: A European Real-World Study on Patient Profiles and Unmet Needs
European Academy of Dermatology and Venereology (EADV), 2025
Interim analysis of a European real-world study on the effectiveness and physician satisfaction of bimekizumab treatment in patients with psoriatic arthritis: Insights from France, Germany, Spain, and the United Kingdom
18th Eilat Conference on New Antiepileptic Drugs and Devices, 2026
Interim Five-Year Results From the Cardiovascular Safety Registry Study of Fenfluramine Oral Solution Exposure in the United States
Congress of Clinical Rheumatology (CCR) East, 2026
Interim Results from an International Multicenter Observational Study of Real-World Bimekizumab Treatment of Psoriatic Arthritis
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Interpreting patient health-related quality-of-life experience with zilucoplan treatment in generalized myasthenia gravis in RAISE and RAISE-XT
International Epilepsy Congress (IEC), 2025
Lennox-Gastaut Syndrome. Situation analysis and Family Journey
European Epilepsy Congress (EEC), 2024
Long-Term Efficacy and Tolerability of Brivaracetam in Pediatric Patients With Focal-Onset Seizures and Cognitive or Learning Comorbidities: Post Hoc Analysis of an Open-Label Trial
Congress of Clinical Rheumatology (CCR) East, 2026
Long-Term Improvements with Bimekizumab Treatment up to 3 Years Assessed by Psoriatic Arthritis Impact of Disease (PsAID)-12
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
American College of Rheumatology (ACR), 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Long-term safety of cyclic rozanolixizumab treatment in patients with generalized myasthenia gravis: A final analysis of Phase 3 studies
American Epilepsy Society (AES), 2025
Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Patients With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
American Epilepsy Society (AES), 2025
Long-Term Use of Oral Lacosamide in Young Children With Epilepsy Who Received Lacosamide in Previous Trials: Data From a Multicenter, Open-Label, Follow-Up Trial
American College of Rheumatology (ACR), 2025
Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Neuromuscular Study Group (NMSG) Annual Scientific Meeting, 2024
Long-term zilucoplan in generalized myasthenia gravis: 96-week follow-up interim analysis of RAISE-XT
American Academy of Neurology (AAN), 2026
Loss of Productivity, Seizure Worry, and Patient and Caregiver Quality of Life Associated With Prolonged Seizures: Results From a Global Real-World Point-in-Time Study
Congress of Clinical Rheumatology West (CCR West), 2025
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Phase 2b/3 Results
European Alliance of Associations for Rheumatology (EULAR), 2025
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Congress of Clinical Rheumatology (CCR) East, 2026
Markers of IL-17 Signaling in the Blood of Patients with Psoriatic Arthritis with Inadequate Response to Tumor Necrosis Factor Inhibitors
European Alliance of Associations for Rheumatology (EULAR), 2025
Markers of IL-17 Signalling in the Blood of Patients with Psoriatic Arthritis with Inadequate Response to Tumour Necrosis Factor Inhibitors
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Measuring the effect of rozanolixizumab treatment in the MycarinG study using the Myasthenia Gravis Impairment Index
State of Texas Association of Rheumatologist (STAR), 2025
Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 years of Bimekizumab Treatment: Results from a Phase 3 Open-label Extension Study
Neuromuscular Study Group (NMSG) Annual Scientific Meeting, 2024
Minimal symptom expression in generalized myasthenia gravis: A post hoc analysis of MycarinG and open-label studies
American Academy of Neurology (AAN), 2026
Missed opportunities for pharmacist intervention among Medicare Fee-for-Service beneficiaries with myasthenia gravis: A real-world claims analysis
European Epilepsy Congress (EEC), 2024
Modeling Systemic Exposure to Fenfluramine and its Active Metabolite, Norfenfluramine, in Patients With Dravet Syndrome
American Epilepsy Society (AES), 2025
Mortality Rates and Risk Factors Among Patients With Lennox-Gastaut Syndrome or Dravet Syndrome
American Academy of Neurology (AAN), 2026
Mortality Rates and Risk Factors Among Patients With Lennox-Gastaut Syndrome or Dravet Syndrome
International Epilepsy Congress (IEC), 2025
Neonatal AAV Gene Therapy Rescues Phenotypes in STXBP1 Haploinsufficient Mice
European Epilepsy Congress (EEC), 2024
Non-seizure benefits of long-term fenfluramine treatment in pediatric patients with Dravet syndrome
European Pediatric Neurology Society (EPNS), 2025
Non-seizure benefits of long-term fenfluramine treatment in pediatric patients with Dravet syndrome
International Epilepsy Congress (IEC), 2025
Non-seizure benefits of long-term fenfluramine treatment in pediatric patients with Dravet syndrome
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Non-steroidal immunosuppressant therapy changes during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Normalisation of molecular signatures associated with pruritus in plaque psoriasis correlates with itch resolution following bimekizumab treatment
International Congress on Neuromuscular Diseases (ICNMD), 2024
Ocular symptoms in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
European Pediatric Neurology Society (EPNS), 2025
Onset and Duration of Adverse Events in Patients Treated With Fenfluramine in the Lennox-Gastaut Syndrome Clinical Trials
American Epilepsy Society (AES), 2025
Patient and Caregiver Perceptions of Acute Seizure Medications and the Rapid and Early Seizure Termination (REST) Approach: Qualitative Interviews
American Academy of Neurology (AAN), 2026
Patient and Caregiver Perceptions of Acute Seizure Medications and the Rapid and Early Seizure Termination (REST) Approach: Qualitative Interviews
American Epilepsy Society (AES), 2025
Patient and Caregiver Preferences for Acute Seizure Medications: A Quantitative Survey
American Academy of Neurology (AAN), 2026
Patient and Caregiver Preferences for Acute Seizure Medications: A Quantitative Survey
American College of Rheumatology (ACR), 2025
Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
American Academy of Neurology (AAN), 2026
Patient treatment preferences in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
European Pediatric Neurology Society (EPNS), 2025
Patients' lived experience of thymidine kinase 2 deficiency (TK2d): results from the Assessment of TK2d Patient Perspectives (ATP) study
American College of Rheumatology (ACR), 2025
Persistence and Disease Activity Control Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Ther
European Epilepsy Congress (EEC), 2024
Pharmacokinetics of Fenfluramine and its Active Metabolite Norfenfluramine in Patients with Lennox-Gastaut Syndrome
International Epilepsy Congress (IEC), 2025
Post Hoc Analysis of Fenfluramine for Lennox-Gastaut Syndrome by Baseline Frequency Quartiles of Seizures Associated With a Fall
American Academy of Neurology (AAN), 2026
Prevalence, Treatment Patterns, and Healthcare Resource Utilization Among Patients With CDKL5 Deficiency Disorder: Retrospective Analysis of US Claims Data
International Epilepsy Congress (IEC), 2025
Prospective evaluation of fenfluramine use in a cohort of pediatric and adult patients with Dravet syndrome
European Pediatric Neurology Society (EPNS), 2025
Prospective evaluation of non-seizure benefits related to treatment with fenfluramine in pediatric and adult patients with Dravet syndrome
European Epilepsy Congress (EEC), 2024
Pulmonary safety of Staccato®alprazolam in healthy participants and participants with mild asthma: phase 1, randomised, double-blind, placebo-controlled trial
Muscular Dystrophy Association (MDA), 2026
Quality of life in patients with generalized myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
Neuromuscular Study Group (NMSG) Annual Scientific Meeting, 2024
Rare Disease Connect in Neurology (RDCN): An international MG community and forum providing needs-driven medical education
American Epilepsy Society (AES), 2025
Reactive Mouse Primary Astrocytes as a Model to Explore Glial Gene Expression Profiles Identified in Human Temporal Lobe Epilepsy
Fall Clinical (FC), 2025
Real-World Clinician- and Patient-Reported Outcomes and Treatment Persistence Following Bimekizumab Initiation in Patients with Psoriasis: 6-Month Results from the PPD CorEvitas Psoriasis Registry
Fall Clinical (FC), 2025
Real-World Dosing Patterns of Biologics for the Treatment of Hidradenitis Suppurativa
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Real-world insights from people living with myasthenia gravis: Analysis of user characteristics and adherence patterns from the HumaMG ap
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Repeated cycles of rozanolixizumab treatment in patients with anti-muscle-specific tyrosine kinase antibody-positive generalized myasthenia gravis
International Epilepsy Congress (IEC), 2025
Rescue of neuronal activity in iPSC-derived STXBP1 in vitro disease models using viral vectors
International Congress on Neuromuscular Diseases (ICNMD), 2024
Response rates with zilucoplan in generalised myasthenia gravis: 120-week interim analysis of RAISE-XT
American Academy of Neurology (AAN), 2026
Response to rozanolixizumab across treatment cycles in patients with generalized myasthenia gravis: A post hoc analysis of final pooled Phase 3 data
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Response to rozanolixizumab in patients with generalized myasthenia gravis: Final pooled analysis of MycarinG and open‑label extension studies
American College of Rheumatology (ACR), 2025
Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: A post hoc analysis of final pooled Phase 3 data
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: Post hoc analysis
Child Neurology Society (CNS), 2025
Safety and Effectiveness of Fenfluramine for the Treatment of Seizures in Lennox-Gastaut Syndrome: Results From the Final Analysis of an Open-Label Extension Study
European Pediatric Neurology Society (EPNS), 2025
Safety and Effectiveness of Fenfluramine for the Treatment of Seizures in Lennox-Gastaut Syndrome: Results From the Final Analysis of an Open-Label Extension Study
International Congress on Neuromuscular Diseases (ICNMD), 2024
Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalised myasthenia gravis (MG0004)
Annual International Congress of the World Muscle Society (WMS), 2025
Safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency: an integrated analysis from a pooled dataset
European Pediatric Neurology Society (EPNS), 2025
Safety, Tolerability, Pharmacokinetics, and Efficacy of Fenfluramine in Combination With Cannabidiol: Results From an Exploratory Phase 1 Study
International Epilepsy Congress (IEC), 2025
Seizure Duration and Time-point Cutoffs for Statistically Defining a Prolonged Seizure: A Post-Hoc Analysis of the SCORE Video-EEG Database
American Academy of Neurology (AAN), 2026
Seizure Duration and Time-point Cutoffs for Statistically Defining a Prolonged Seizure: A Post-Hoc Analysis of the SCORE Video-EEG Database
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design
American College of Rheumatology (ACR), 2025
Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results From Two Phase 3 Studies and Their Open-Label Extension
Congress of Clinical Rheumatology (CCR) East, 2026
Skin/Joint Symptom Control and Patient-Reported Outcomes in Psoriatic Arthritis with Biologic/Targeted Synthetic Antirheumatic Drugs
American Academy of Neurology (AAN), 2026
Streamlining the Process of Caregiving for a Loved One With Dravet or Lennox-Gastaut Syndrome
American Epilepsy Society (AES), 2025
Streamlining the Process of Caregiving for a Loved One with Dravet or Lennox-Gastaut Syndrome
European Pediatric Neurology Society (EPNS), 2025
Survival analyses in patients with thymidine kinase 2 deficiency aged ≤12 years at symptom onset who received pyrimidine nucleos(t)ide therapy
European Pediatric Neurology Society (EPNS), 2025
Survival analysis in untreated patients with thymidine kinase 2 deficiency (TK2d) aged ≤12 years at TK2d symptom onset: findings from the largest international TK2d dataset
European Society of Human Genetics Conference (ESHG), 2025
Survival, functional outcomes and safety in patients with thymidine kinase 2 deficiency (TK2d) and an age of TK2d symptom onset ≤12 years who received pyrimidine nucleos(t)ide therapy
American College of Rheumatology (ACR), 2025
Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
European Alliance of Associations for Rheumatology (EULAR), 2025
Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Sustained minimal symptom expression in generalized myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
Muscular Dystrophy Association (MDA), 2026
Sustained minimal symptom expression in generalized myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
American Academy of Neurology (AAN), 2026
Sustained minimal symptom expression in generalized myasthenia gravis: A 120-week post hoc analysis of RAISE-XT
Skin Inflammation & Psoriasis International Network (SPIN), 2025
Sustained reduction in pain and fatigue with bimekizumab treatment in patients with active psoriatic arthritis over 3 years: Results from two phase 3 studies
Muscular Dystrophy Association (MDA), 2026
Switching to rozanolixizumab from efgartigimod: Real-world outcomes in patients with generalized myasthenia gravis in the United States
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study
13th Annual University of California, Irvine (UCI) Neuromuscular Colloquium, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study
International Congress on Neuromuscular Diseases (ICNMD), 2024
Switching to subcutaneous zilucoplan from IV C5 inhibitors in myasthenia gravis: A Phase 3b study
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2024
Switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis: A Phase 3b study
United Mitochondrial Medicine Foundation (UMDF) Mitochondrial Medicine Conference, 2025
The disease course of untreated patients with thymidine kinase 2 deficiency (TK2d) aged >12 years at TK2d symptom onset: findings from the largest international TK2d dataset
United Mitochondrial Medicine Foundation (UMDF) Mitochondrial Medicine Conference, 2025
The disease course of untreated patients with thymidine kinase 2 deficiency (TK2d) aged ≤12 years at TK2d symptom onset: findings from the largest international TK2d dataset
European Academy of Dermatology and Venereology (EADV), 2025
The journey of patients with hidradenitis suppurativa in Denmark and Norway: Real-world data from the HISREG registry
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
The long-term effectiveness of zilucoplan in myasthenia gravis: Predictive modeling in a US real-world database
American College of Rheumatology (ACR), 2025
The SpA Puzzle: Unraveling Inflammation Piece by Piece
American Epilepsy Society (AES), 2025
Tolerability and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients With Focal Seizures: Phase 3, Open-Label Extension Trial
Child Neurology Society (CNS), 2025
Tolerability and Safety of Fenfluramine and Global Functioning of Patients in a Combined Open-label Extension Study of Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
International Epilepsy Congress (IEC), 2025
Tolerability and Safety of Fenfluramine and Global Functioning of Patients in a Combined Open-label Extension Study of Children and Adults With Dravet and Lennox-Gastaut Syndromes
American Academy of Neurology (AAN), 2026
Treatment characteristics and healthcare resource utilization among patients with generalized myasthenia gravis initiating rozanolixizumab in the United States
European Epilepsy Congress (EEC), 2024
Treatment satisfaction, work productivity, and quality of life under adjunctive brivaracetam in earlier treatment lines in adults with focal-onset seizures: 12-month real-world data from BRITOBA
International Epilepsy Congress (IEC), 2025
Understanding and Optimising the Seizure Emergency Pathway
American Academy of Neurology (AAN), 2026
Understanding Frequency and Characteristics of Prolonged Seizures Using Seizure Diary Data
American Academy of Dermatology (AAD), 2026
Unmet needs in atopic dermatitis treated with current biologic therapies: results from an international cross-sectional cohort study
International Epilepsy Congress (IEC), 2025
Unpredictable Seizures and Disruptive Behavior in Developmental and Epileptic Encephalopathies: Interim Results of a Caregiver Survey
International Epilepsy Congress (IEC), 2025
Use of Fenfluramine and Cannabidiol in Daily Practice: A Retrospective Analysis of German Prescription Claims
European Pediatric Neurology Society (EPNS), 2025
Use of Fenfluramine and Cannabidiol in Daily Practice: A Retrospective Analysis of German Prescription Claims
Genomics of Rare Disease (GRD), 2025
Using the Genomics England National Genomic Research Library (NGRL) and UK Biobank to investigate the genetic, phenotypic and clinical landscape of thymidine kinase 2 deficiency (TK2d)
European Pediatric Neurology Society (EPNS), 2025
Using the Genomics England National Genomic Research Library (NGRL) and UK Biobank to investigate the genetic, phenotypic and clinical landscape of thymidine kinase 2 deficiency (TK2d)
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2025
Zilucoplan treatment of severe exacerbations leading to hospitalization in generalized myasthenia gravis: Study design